Division of Medicinal Chemistry, Amsterdam Institute for Molecules Medicines and Systems, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Division of Medicinal Chemistry, Amsterdam Institute for Molecules Medicines and Systems, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Mol Pharmacol. 2019 Dec;96(6):735-736. doi: 10.1124/mol.119.118364. Epub 2019 Oct 17.
Chemokine receptors CXCR4 and atypical chemokine receptor 3 (ACKR3/CXCR7) are highly expressed in a range of tumors. Yet, their role in cancer progression is not well understood. This minireview series encompasses seven comprehensive reviews focusing on modulators (small molecules, pepducins, antibodies), structural aspects, spatio-temporal signaling properties, and phosphorylation/interactome of CXCR4 and ACKR3. Moreover, different (patho)physiologic aspects and roles of these receptors in immunologic and oncogenic processes are discussed. SIGNIFICANCE STATEMENT: CXCR4 and atypical chemokine receptor 3 are two oncogenic G protein-coupled receptors that are highly upregulated in various tumors. Insight into the signalling properties of these receptors and the availability of modulators targeting these receptors are essential to assess their role in cancer.
趋化因子受体 CXCR4 和非典型趋化因子受体 3(ACKR3/CXCR7)在多种肿瘤中高度表达。然而,它们在癌症进展中的作用尚不清楚。本综述系列包括七篇综述,重点介绍了趋化因子受体 CXCR4 和 ACKR3 的调节剂(小分子、肽聚糖、抗体)、结构方面、时空信号特性和磷酸化/相互作用组。此外,还讨论了这些受体在免疫和致癌过程中的不同(病理)生理方面和作用。意义陈述:趋化因子受体 CXCR4 和非典型趋化因子受体 3 是两种致癌的 G 蛋白偶联受体,在各种肿瘤中高度上调。深入了解这些受体的信号特性以及针对这些受体的调节剂的可用性对于评估它们在癌症中的作用至关重要。